dpp-4 inhibitors and glp-1 agonists GLP-1RAs: cardiovascular safety and benefits GLP-1 Receptor Agonists Have better

10.1016/j.cardfail.2019.05.007 23 ElsanhouryA.NelkiV.KelleS.Van LinthoutS.TschpeC

An elevated resting heart rate can increase long-term cardiovascular risk, and regulators need robust data confirming that the metabolic benefits outweigh this potential downside

We are highlighting amylin as the hottest new mechanism for obesity, Leerink Partners analysts wrote in a Tuesday note to investors, explaining that amylin mostly works as a satiety signal and affects hedonic aspects of eating. The molecule acts on several regions of the brain to lower the feeling of being rewarded after eating

The compound appears to act as both a substrate and inhibitor of these enzymes, which metabolize numerous medications

Eur J Endocrinol 181(6):R211R234 Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V et al (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis